Dr Christos Mikropoulos
Consultant Clinical Oncologist
MBBS, MSc, MD (Res), MRCP, FRCR
GMC: 4692210
MBBS, MSc, MD (Res), MRCP, FRCR
GMC: 4692210
Qualifications
- MBBS — Aristotle University of Thessaloniki (1998)
- MSc — Newcastle University (2007, Merit)
- MRCP — Royal College of Physicians (2008)
- FRCR — Royal College of Radiologists (2013)
- MD (Res) — Institute of Cancer Research, University of London (2015)
Professional Memberships
- Royal College of Physicians (MRCP)
- Royal College of Radiologists (FRCR)
- European Society for Medical Oncology (ESMO)
- European Society for Radiotherapy & Oncology (ESTRO)
Dr Christos Mikropoulos Introduction
A UK leader in prostate cancer care
Christos has studied at leading institutions across the UK and is currently a clinical oncologist at Mount Alvernia Hospital in Guildford. He treats people with a range of cancers but has particular expertise in radiotherapy, including stereotactic ablative radiotherapy and prostate brachytherapy. At The Focal Therapy Clinic, he is a key member of our MDTs and helps people choose the right treatment for them.
Christos is also at the cutting edge of prostate cancer research. In addition to treating patients, he is co-investigator and developer of a number of studies at the Institute of Cancer Research, including the GENPROS study (investigating how genetic factors impact outcomes), the GENPET study (an imaging study looking at men with different genetic mutations) and the BARCODE-1 study (where 5,000 men will be genetically profiled and the highest risk individuals will be offered a diagnostic prostatic biopsy).
Hear what Dr Christos Mikropoulos has to say about Focal Therapy
Dr Christos Mikropoulos: Are black men more likely to get prostate cancer
00:27
Playlist
Christos Consultant Page
SUMMARY
Dr. Christos Mikropoulos (Oncologist, The Focal Therapy Clinic): Black men are twice as likely to develop prostate cancer as white men, with 1 in 4 at risk. Family history further increases the risk, making PSA screening and proactive health checks essential for early detection and better outcomes. Dr Christos Mikropoulos - https://www.thefocaltherapyclinic.co.uk/about-us/our-consultants/dr-christos-mikropoulos/ prostate cancer in black males - https://www.thefocaltherapyclinic.co.uk/blog/prostate-cancer-black-males/ Errol McKeller - https://www.thefocaltherapyclinic.co.uk/living-with-prostate-cancer/prostate-cancer-screening-for-black-men-1-in-4/ genetic screening - https://www.thefocaltherapyclinic.co.uk/blog/prostate-cancer-genetic-screening/ Website: https://www.thefocaltherapyclinic.co.uk LinkedIn: linkedin.com/company/the-focal-therapy-clinic/ Facebook: facebook.com/TheFocalTC Telephone: +44 (0) 207 036 8870 #ProstateCancer #MensHealth #CancerScreening #PSATest #EarlyDetection #ProstateHealth
This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Read more.
Dr Christos Mikropoulos: How long can I live with prostate cancer?
00:23
Playlist
Christos Consultant Page
SUMMARY
Dr. Christos Mikropoulos (Oncologist, The Focal Therapy Clinic): Life expectancy with prostate cancer depends on the stagelocalized cancer often allows for a normal lifespan, while advanced cases may shorten life expectancy. However, many men live for years even with metastases, thanks to modern treatments and ongoing medical advancements. Dr Christos Mikropoulos - https://www.thefocaltherapyclinic.co.uk/about-us/our-consultants/dr-christos-mikropoulos/ How long can you live with prostate cancer without treatment - https://www.thefocaltherapyclinic.co.uk/living-with-prostate-cancer/prognosis-and-survival/ living with prostate cancer - https://www.thefocaltherapyclinic.co.uk/living-with-prostate-cancer/
This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Read more.
Dr Christos Mikropoulos When is radiotherapy more appropriate than Prostatectomy
00:45
Playlist
Christos Consultant Page
SUMMARY
Dr. Christos Mikropoulos (Oncologist, The Focal Therapy Clinic): Patients with localized prostate cancer are offered all treatment options, including surgery, radiotherapy, and focal therapy. Both surgery and radiotherapy are effective, and the choice is made through an informed consent process, ensuring patients understand risks, benefits, and long-term outcomes.
This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Read more.
Professional Qualifications
- Clinical Oncology at the Royal Marsden, Guy’s and St Thomas’s and Kent Oncology Centre
- MRCP – 2008
- MSc in Oncology (Newcastle University) – 2007
- FRCR – 2013
- MD (research) in Cancer Genetics, University of London, Institute of Cancer Research (ICR) – 2015
Professional Affiliations
- Member of the Royal College of Physicians (MRCP)
- Fellow of the Royal College of Radiologists (FRCP)
- Member of the European Society of Medical Oncology (ESMO)
- Member of the European Society of Therapeutic Radiation Oncology (ESTRO)
Current Appointment
- Clinical Oncologist at Mount Alvernia Hospital
Research and publications
- A Prospective Prostate Cancer Screening Programme for Men with Pathogenic Variants in Mismatch Repair Genes (IMPACT): Initial Results from an International Prospective Study. Lancet Oncology. 2021. https://doi.org/10.1016/S1470-2045(21)00522-2
- Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study. European Urology. 2026. https://doi.org/10.1016/j.eururo.2026.01.031
- Long-term Survival After Low-dose-rate Brachytherapy for Prostate Cancer: The Royal Surrey Experience. BJU International. 2021. https://doi.org/10.1111/bju.15585
- Low-Dose-Rate Prostate Brachytherapy (LDR-PB) Adopts Postsurgical PSA Value for Definition of Cure. BJUI Compass. 2020. https://doi.org/10.1002/bco2.49
- Prostate Cancer Germline Variations and Implications for Screening and Treatment. Cold Spring Harbor Perspectives in Medicine. 2018. https://doi.org/10.1101/cshperspect.a030379
- An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer. Diagnostics (Basel). 2020. https://doi.org/10.3390/diagnostics10080549
- IMPACT Study: Targeted Prostate Cancer Screening. The Oncologist. 2013. https://doi.org/10.1634/theoncologist.2013-0221
- State-of-the-Art Molecular Oncology in UK. International Journal of Molecular Sciences. 2023. https://doi.org/10.3390/ijms24119336
Learn more about Focal Therapy and Prostate Cancer
Survey of Prostate Cancer Patients Reveals Severe Knowledge Gaps Among Men
Length: 6 min read Key Takeaways A survey of 243 prostate cancer patients revealed major...
How Accurate is a Urine test for Prostate Cancer – and can it replace PSA or MRI?
Author: The Focal Therapy Clinic Length: 8 min read Published: 14 May 2026 Medically Reviewed:...
Is Testosterone Replacement Therapy Safe After Prostate Cancer Treatment?
Author: The Focal Therapy Clinic Length: 8 min read Published: 14 May 2026 Medically Reviewed:...
Frequently asked questions
What is Dr Christos Mikropoulos's expertise in prostate cancer treatment?
Dr Christos Mikropoulos is a UK-leading consultant clinical oncologist specialising in advanced prostate cancer radiotherapy techniques. His expertise includes Stereotactic Ablative Radiotherapy (SABR), which delivers highly precise radiation in fewer sessions, and prostate brachytherapy (both low-dose-rate and high-dose-rate seed implants). He is particularly experienced in treating oligometastatic prostate cancer using SABR, a cutting-edge approach for patients with limited metastatic disease. Dr Mikropoulos holds GMC registration 4692210 and is a Fellow of the Royal College of Radiologists (FRCR).
What is Stereotactic Ablative Radiotherapy (SABR) for prostate cancer?
Stereotactic Ablative Radiotherapy (SABR) is an advanced radiation technique that delivers extremely precise, high-dose radiation to prostate cancer in just 5 treatment sessions instead of the traditional 20–37 sessions. Using sophisticated image guidance and beam-shaping technology, SABR targets the prostate with millimetre accuracy while sparing surrounding organs. This approach offers equivalent cancer control to conventional radiotherapy but with greatly improved convenience, completing treatment in under 2 weeks rather than 2 months, and potentially reducing side effects. Dr Mikropoulos is a recognised expert in prostate SABR and has contributed to research advancing the technique.
How does prostate brachytherapy differ from standard external beam radiation?
Prostate brachytherapy delivers radiation internally using radioactive seeds implanted directly into the prostate gland, unlike external beam radiotherapy which directs radiation from outside the body. This internal method allows higher radiation doses to be delivered precisely to the prostate while reducing exposure to surrounding organs such as the bladder and rectum. Brachytherapy is available as permanent low-dose-rate seeds that remain in the gland, or temporary high-dose-rate treatment delivered through removable catheters. Treatment usually requires 1–3 sessions rather than daily visits for several weeks. Dr Mikropoulos specialises in both forms of brachytherapy.
Who is suitable for oligometastatic SABR treatment?
Oligometastatic SABR is suitable for prostate cancer patients with a small number of metastatic sites, typically 1–5 lesions visible on advanced imaging such as PSMA PET-CT or whole-body MRI. This state sits between localised and widespread metastatic disease, where targeted treatment to each metastasis may delay progression and possibly extend survival. Ideal candidates have good performance status, stable primary disease, treatable metastases in the bones or lymph nodes, and no rapidly advancing cancer. Dr Mikropoulos has published research on oligometastatic SABR and assesses patients for this approach within his oncology practice.
What cancer research is Dr Mikropoulos involved in?
Dr Mikropoulos is involved in research at the Institute of Cancer Research, University of London, acting as co-investigator on several major studies. His work includes the GENPROS study on genetic factors influencing prostate cancer outcomes, the GENPET study using advanced imaging in men with different genetic mutations, and the BARCODE-1 project profiling 5,000 men to identify those at highest risk who may benefit from early biopsy. He has authored papers in leading journals, including The Lancet Oncology, covering topics such as hormone therapy optimisation, brachytherapy outcomes, and oligometastatic disease. His MD in Cancer Genetics highlights his commitment to evidence-based advancement of cancer treatment.
Can Dr Mikropoulos review my case for testicular, bladder, or colorectal cancer?
Yes. Although widely known for his prostate cancer expertise, Dr Mikropoulos is a consultant clinical oncologist specialising in urogenital, gynaecological, and colorectal cancers. His practice includes managing testicular cancer, bladder cancer using radiotherapy or combined approaches, and colorectal cancer. His training at major UK centres such as the Royal Marsden, Guy's and St Thomas's, and the Kent Oncology Centre, along with his FRCR and MRCP qualifications, supports his broad oncology expertise. Patients can arrange appointments at The Focal Therapy Clinic or Mount Alvernia Hospital.
What are Dr Mikropoulos's qualifications and training?
Dr Christos Mikropoulos holds MBBS (1998) from Aristotle University of Thessaloniki, MSc in Oncology with Merit (2007) from Newcastle University, MRCP (2008), FRCR (2013), and MD (Research) in Cancer Genetics (2015) from the Institute of Cancer Research, University of London. He trained in clinical oncology at the Royal Marsden, Guy's and St Thomas's, and the Kent Oncology Centre. He is a member of ESMO and ESTRO. His GMC registration number is 4692210. This background establishes him as a highly qualified specialist in clinical and radiation oncology.
Any questions?
If you’ve got any questions about your prostate cancer diagnosis or want to know more about HIFU or NanoKnife, don’t hesitate to get in touch with our friendly, knowledgeable team.
Contact the team
Subscribe to our newsletter
Get expert advice & the latest prostate cancer research - straight to your inbox.
We care about your data in our privacy policy.
